We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dengue Rapid Diagnostic Tests Recycled For Serotyping

By LabMedica International staff writers
Posted on 25 May 2016
Image: The SD Bioline Dengue Duo Rapid Diagnostic Test (RDT) (Photo courtesy of Standard Diagnostics).
Image: The SD Bioline Dengue Duo Rapid Diagnostic Test (RDT) (Photo courtesy of Standard Diagnostics).
Dengue virus infection causes major public health problems in tropical and subtropical areas, but in many endemic areas, inadequate access to laboratory facilities is a major obstacle to surveillance and study of dengue epidemiology.

Dengue Rapid Diagnostic Tests (RDT), in which a drop of blood is loaded onto a paper strip in a plastic cassette, are simple to use and have good diagnostic accuracy. However, four types of dengue virus circulate in most tropical areas and their patterns of circulation are of epidemiological importance since they play a role in the severity and propagation of the disease.

An international team of tropical medicine specialists led by those at Mahidol University (Salaya, Thailand) collected blood samples from 99 consenting patients admitted with symptoms meeting the international criteria for dengue infection from August to November 2013. At another hospital 362 consenting patients with undifferentiated fever who tested negative by malaria RDT were enrolled from July to October 2012, and both venous whole blood and capillary whole blood from finger pricks were collected.

The samples were assayed with the SD Bioline Dengue Duo RDT (Standard Diagnostics, Kyonggi-do, Korea) which is an in vitro immunochromatographic assay for the detection of dengue virus NS1 Ag and anti-dengue IgM/IgG antibodies in human serum, plasma, or whole blood, from finger-prick or venous blood. This test comprises a pair of test devices, a dengue NS1 Ag test on the left side, and a dengue IgM/IgG antibody (Ab) test on the right side. Dengue RNA was purified from the sample pad of the NS1 RDT loaded with virus isolates of the four serotypes, then quantified by real time reverse transcriptase polymerase chain reaction (RT-PCR).

All dengue positive neat, RDT and filter paper (FP) samples were tested by real-time RT-PCR for serotyping. All four DENV serotypes were found, with the majority of patients having DENV-3 (81%; 42/52) followed by DENV-2 (10%; 5/52), DENV-4 (4%; 2/52), and DENV-1(4%; 2/52) with one sample that could not be typed. There was 100% concordance between RDT and serum RT-PCR of infecting dengue serotype. The dengue serotypes at in the rural area at Salavan were mostly DENV-1 (80%; 113/142) followed by DENV-2 (12%; 17/142) and DENV-3 (4%; 6/142).

The authors concluded that their technique may also permit dengue envelope sequencing for deeper molecular epidemiology analysis from RNA purified from RDTs. This could greatly increase availability of dengue epidemiological data from previously inaccessible tropical areas by facilitating dengue confirmation tests and strain identification to aid surveillance and public health interventions. The study was published on May 9, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Mahidol University
Standard Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
POC Immunoassay Analyzer
Procise DX

Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more